Synopsis

Source of validity: Scientific
Rating (out of 5): 3

The use of hemp oil—more specifically, CBD (cannabidiol), a compound found in hemp—has gained scientific attention as a treatment for epilepsy, particularly drug-resistant forms such as Dravet syndrome and Lennox-Gastaut syndrome. Several well-designed clinical trials, including randomized, double-blind, placebo-controlled studies, have demonstrated that pharmaceutical-grade CBD can significantly reduce the frequency of seizures in some patients with these severe epileptic conditions. This has led to the approval of Epidiolex, a purified CBD oral solution, by the U.S. Food and Drug Administration (FDA) for these specific types of epilepsy.

It is important to distinguish between hemp oil (which may or may not contain significant amounts of CBD, depending on the extraction process) and CBD oil, which is specifically formulated to contain high levels of cannabidiol. Most scientific evidence pertains to purified CBD, not generic hemp seed oil, which contains little to no CBD. The mechanism of action is not fully understood, but CBD is believed to modulate neuronal excitability and neurotransmitter release through its effects on the endocannabinoid system and other receptor pathways.

While the evidence is strong for certain rare forms of epilepsy, it is less conclusive for other types of seizures, and further research is warranted. Additionally, the safety profile of CBD is generally favorable, though side effects and drug interactions can occur. The use of generic hemp oil for epilepsy, without standardized CBD content, is not substantiated by clinical evidence.

More about hemp oil
More about Epilepsy

Other ingredients used for Epilepsy

Other health conditions supported by hemp oil

Products containing hemp oil